Limitations in the CAR-T therapy for diffuse large B-cell lymphoma

Sehn, L. H., & Salles, G. (2021). Diffuse Large B-Cell Lymphoma. The New England journal of medicine, 384(9), 842–858.

Chow, V. A., Shadman, M., & Gopal, A. K. (2018). Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood, 132(8), 777–781.

Sadelain, M., Brentjens, R., & Rivière, I. (2013). The basic principles of chimeric antigen receptor design. Cancer discovery, 3(4), 388–398.

Riedell, P. A., & Bishop, M. R. (2020). Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Therapeutic advances in hematology, 11, 2040620720902899.

Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007). Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity, 27(1), 111–122.

Zhang, Z., Chen, X., Tian, Y., Li, F., Zhao, X., Liu, J., Yao, C., & Zhang, Y. (2020). Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. Journal for immunotherapy of cancer, 8(2), e001150.

Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 11(4), 69.

Sterner R, Kenderian S. Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. Curr. Opin. in Hematol. 2020; 27: 41–48.

Hopfinger, G., Jäger, U., & Worel, N. (2019). CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. HemaSphere, 3(2), e185.

Anthony Walker, Robert Johnson; Commercialization of cellular immunotherapies for cancer. Biochem Soc Trans 15 April 2016; 44 (2): 329–332.

Read more here: Source link